東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

ImmunoPET/Fluorescence Imaging and R...

Tsai, Wen-Ting Katie.

FindBook

Google Book

Amazon

博客來

ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer./
作者:	Tsai, Wen-Ting Katie.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	133 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-06, Section: B.
Contained By:	Dissertations Abstracts International80-06B.
標題:	Biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13422853
ISBN:	9780438748811

ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer.
Tsai, Wen-Ting Katie.

ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 133 p.

Source: Dissertations Abstracts International, Volume: 80-06, Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2018.

This item is not available from ProQuest Dissertations & Theses.

Prostate cancer diagnosis and treatment options need to be improved as over- and under-treatment, as well as disease recurrence and resistance to current therapies, continue to be challenges. Prostate stem cell antigen (PSCA) is overexpressed in the majority of prostate cancers and correlates with grade, stage, and metastatic potential. Antibodies, which are highly specific for their target, can be labeled with radionuclides and fluorophores for molecular imaging and therapy. This dissertation describes the use of humanized anti-PSCA antibody fragments for dual-modality immuno-positron emission tomography (immunoPET)/fluorescence imaging and for radioimmunotherapy of prostate cancer in preclinical models. Prostate cancer visualization could be improved by using immunoPET for preoperative non-invasive disease detection, and fluorescence imaging for intraoperative guidance of tumor resection; the power of both imaging modalities can be combined on a single agent. In this work, the dual-labeled humanized anti-PSCA A11 cys-minibody (A11 cMb) was evaluated for successive immunoPET/fluorescence imaging in subcutaneous and orthotopic prostate cancer models. A11 cMb was site-specifically conjugated with the near-infrared fluorophore Cy5.5 and radiolabeled with 124I or 89Zr. 124I- and 89Zr-A11 cMb-Cy5.5 were used to detect subcutaneous and intraprostatic PSCA-positive tumors. High contrast immunoPET/fluorescence imaging with 124I-A11 cMb-Cy5.5 identified both high PSCA-expression and moderate PSCA-expression subcutaneous tumors. 89Zr-A11 cMb-Cy5.5 immunoPET showed uptake in the prostate without interfering signal in the bladder, and ex vivo fluorescence imaging clearly showed signal in the tumor and not the surrounding seminal vesicles. These studies support the potential for dual-modality A11 cMb to be translated for preoperative whole-body disease detection and real-time surgical guidance in prostate cancer patients. Prostate cancer that metastasizes often becomes resistant to current therapies and eventually progresses, and alternative therapy options include radioimmunotherapy which delivers a high radiation dose to the tumor with the aim of minimizing dose to normal organs. Anti-PSCA antibody fragments radiolabeled with a cytotoxic radionuclide, such as the beta-emitter 131I or 177Lu, may be effective for radioimmunotherapy with lower toxicity compared to intact antibodies. 124I- and 89Zr-A11 minibody (A11 Mb) immunoPET was used to guide dosimetry studies, and 131I- and 177Lu-A11 Mb was administered to 22Rv1-PSCA s.c. tumor-bearing nude mice to complete dosimetry estimation. 131I-A11 Mb had a higher projected therapeutic index, or tumor-to-radiosensitive tissue dose, and was used in subsequent therapy studies. 131I-A11 Mb inhibited PSCA-positive tumor growth in a dose-dependent manner and extended survival with minimal off-target toxicity. Additionally, preliminary biodistribution studies in knock-in transgenic mice that express human-PSCA were similar to that of nude mice. Therefore, radioimmunotherapy will likely not be toxic to organs with normal PSCA expression (stomach, bladder), and A11 Mb may be suitable for human translation. The results of this work demonstrate the potential of anti-PSCA minibodies as theranostic agents for disease diagnosis, surgical guidance, and treatment. Additionally, the success of anti-PSCA dual-modality imaging and radioimmunotherapy in preclinical models support further evaluation in the clinic.

ISBN: 9780438748811Subjects--Topical Terms:

522710
Biology.

ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer.
LDR:04692nmm a2200349 4500 001 2210675
005 20191121124255.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438748811
035 $a (MiAaPQ)AAI13422853
035 $a (MiAaPQ)ucla:17456
035 $a AAI13422853
040 $a MiAaPQ $c MiAaPQ
100 1 $a Tsai, Wen-Ting Katie. $3 3437812
245 1 0 $a ImmunoPET/Fluorescence Imaging and Radioimmunotherapy of PSCA-Positive Prostate Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 133 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-06, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Wu, Anna M.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2018.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
520 $a Prostate cancer diagnosis and treatment options need to be improved as over- and under-treatment, as well as disease recurrence and resistance to current therapies, continue to be challenges. Prostate stem cell antigen (PSCA) is overexpressed in the majority of prostate cancers and correlates with grade, stage, and metastatic potential. Antibodies, which are highly specific for their target, can be labeled with radionuclides and fluorophores for molecular imaging and therapy. This dissertation describes the use of humanized anti-PSCA antibody fragments for dual-modality immuno-positron emission tomography (immunoPET)/fluorescence imaging and for radioimmunotherapy of prostate cancer in preclinical models. Prostate cancer visualization could be improved by using immunoPET for preoperative non-invasive disease detection, and fluorescence imaging for intraoperative guidance of tumor resection; the power of both imaging modalities can be combined on a single agent. In this work, the dual-labeled humanized anti-PSCA A11 cys-minibody (A11 cMb) was evaluated for successive immunoPET/fluorescence imaging in subcutaneous and orthotopic prostate cancer models. A11 cMb was site-specifically conjugated with the near-infrared fluorophore Cy5.5 and radiolabeled with 124I or 89Zr. 124I- and 89Zr-A11 cMb-Cy5.5 were used to detect subcutaneous and intraprostatic PSCA-positive tumors. High contrast immunoPET/fluorescence imaging with 124I-A11 cMb-Cy5.5 identified both high PSCA-expression and moderate PSCA-expression subcutaneous tumors. 89Zr-A11 cMb-Cy5.5 immunoPET showed uptake in the prostate without interfering signal in the bladder, and ex vivo fluorescence imaging clearly showed signal in the tumor and not the surrounding seminal vesicles. These studies support the potential for dual-modality A11 cMb to be translated for preoperative whole-body disease detection and real-time surgical guidance in prostate cancer patients. Prostate cancer that metastasizes often becomes resistant to current therapies and eventually progresses, and alternative therapy options include radioimmunotherapy which delivers a high radiation dose to the tumor with the aim of minimizing dose to normal organs. Anti-PSCA antibody fragments radiolabeled with a cytotoxic radionuclide, such as the beta-emitter 131I or 177Lu, may be effective for radioimmunotherapy with lower toxicity compared to intact antibodies. 124I- and 89Zr-A11 minibody (A11 Mb) immunoPET was used to guide dosimetry studies, and 131I- and 177Lu-A11 Mb was administered to 22Rv1-PSCA s.c. tumor-bearing nude mice to complete dosimetry estimation. 131I-A11 Mb had a higher projected therapeutic index, or tumor-to-radiosensitive tissue dose, and was used in subsequent therapy studies. 131I-A11 Mb inhibited PSCA-positive tumor growth in a dose-dependent manner and extended survival with minimal off-target toxicity. Additionally, preliminary biodistribution studies in knock-in transgenic mice that express human-PSCA were similar to that of nude mice. Therefore, radioimmunotherapy will likely not be toxic to organs with normal PSCA expression (stomach, bladder), and A11 Mb may be suitable for human translation. The results of this work demonstrate the potential of anti-PSCA minibodies as theranostic agents for disease diagnosis, surgical guidance, and treatment. Additionally, the success of anti-PSCA dual-modality imaging and radioimmunotherapy in preclinical models support further evaluation in the clinic.
590 $a School code: 0031.
650 4 $a Biology. $3 522710
650 4 $a Medical imaging. $3 3172799
650 4 $a Oncology. $3 751006
690 $a 0306
690 $a 0574
690 $a 0992
710 2 $a University of California, Los Angeles. $b Molecular and Medical Pharmacology. $3 3286001
773 0 $t Dissertations Abstracts International $g 80-06B.
790 $a 0031
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13422853